Treatment of Chronic Urticaria in Children

Initial Therapy

The American Academy of Allergy, Asthma, and Immunology recommends starting with a standard dose of a second-generation non-sedating H1 antihistamine, such as cetirizine, loratadine, fexofenadine, desloratadine, or levocetirizine, at age-appropriate dosing, and increasing the dose up to 4 times the standard dose if symptoms persist after 2-4 weeks, before considering additional therapies, with a strength of evidence based on clinical guidelines 1, 2
The British Association of Dermatologists suggests that these medications are the cornerstone of management and should be taken daily, not as needed, with a recommendation to trial at least two different non-sedating antihistamines, as individual responses and tolerance vary between children, supported by evidence from the British Journal of Dermatology 3, 4

The American Academy of Allergy, Asthma, and Immunology recommends increasing the antihistamine dose up to 4 times the standard dose if symptoms are not controlled after 2-4 weeks, with approximately 50% of pediatric patients requiring step 2 or higher dosing to achieve control, and younger children (2-6 years) more likely to need dose escalation, based on evidence from the Journal of Allergy and Clinical Immunology 1, 2
The British Association of Dermatologists supports this approach, which exceeds manufacturer's licensed recommendations, but is supported when potential benefits outweigh risks, with evidence from the British Journal of Dermatology 3, 4

The American Academy of Allergy, Asthma, and Immunology suggests that first-generation antihistamines, such as hydroxyzine or chlorpheniramine, may be added at night for additional symptom control and to help with sleep in resistant cases, but should be avoided as first-line monotherapy due to sedating properties, based on evidence from the British Journal of Dermatology 3, 2
The American Academy of Allergy, Asthma, and Immunology recommends considering adding montelukast as adjunctive therapy, particularly for aspirin-sensitive or autoimmune urticaria, with evidence from Praxis Medical Insights 5
The American Academy of Allergy, Asthma, and Immunology suggests that adding H2 antihistamines, such as ranitidine or famotidine, may be helpful for resistant cases, with evidence from Praxis Medical Insights 5

The British Association of Dermatologists recommends restricting oral corticosteroids to short courses (3-10 days) for severe acute exacerbations or angioedema affecting the mouth, and avoiding long-term oral corticosteroids in chronic urticaria except in very selected cases under specialist supervision, with evidence from the British Journal of Dermatology and Praxis Medical Insights 3, 2, 5

The American Academy of Allergy, Asthma, and Immunology recommends using an "as much as needed and as little as possible" approach by stepping up and stepping down treatment based on disease control, and not stepping down higher-than-standard antihistamine doses before completing at least 3 consecutive months of complete control, with evidence from the Journal of Allergy and Clinical Immunology 1
The American Academy of Allergy, Asthma, and Immunology suggests reducing the daily dose by no more than 1 tablet per month during step-down, and returning to the last dose that provided complete control if control is lost during step-down, with evidence from the Journal of Allergy and Clinical Immunology 1

The American Academy of Allergy, Asthma, and Immunology recommends identifying and minimizing aggravating factors, including overheating, stress, alcohol, and certain medications (aspirin, NSAIDs, codeine), with evidence from Praxis Medical Insights 2, 5, 4
The American Academy of Allergy, Asthma, and Immunology suggests providing patient and parent education about prognosis, with approximately 50% of patients with chronic urticaria being clear by 6 months, though those with angioedema have a poorer outlook, with evidence from Praxis Medical Insights 2, 4
The American Academy of Allergy, Asthma, and Immunology recommends applying cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) for symptomatic relief, with evidence from Praxis Medical Insights 5

The American Academy of Allergy, Asthma, and Immunology recommends administering intramuscular epinephrine (150 µg for children 15-30 kg, 300 µg for those over 30 kg) for anaphylaxis or severe laryngeal angioedema, with evidence from Praxis Medical Insights 2

The international urticaria guidelines recommend a 3-step approach for managing urticaria, with montelukast as an adjunctive option, starting with standard-dose non-sedating H1 antihistamines, then adding omalizumab, and finally cyclosporine for non-responders 6, 7, 8
The American Academy of Allergy, Asthma, and Immunology recommends starting with standard-dose non-sedating H1 antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, or levocetirizine) and increasing up to 4 times the standard dose if inadequate response after 2-4 weeks 6, 7, 8
For patients failing high-dose antihistamines, omalizumab 300 mg every 4 weeks is the recommended second-line therapy, with an allowance of up to 6 months for response before considering alternatives 6, 7, 8

The American College of Allergy, Asthma, and Immunology advises against delaying omalizumab in patients with severe, refractory disease who clearly meet criteria for second-line therapy, and against using montelukast as monotherapy, always maintaining antihistamine therapy 6, 7, 8
The guidelines recommend avoiding long-term corticosteroids while trialing montelukast, with short courses (3-10 days) only for severe exacerbations 6, 7, 8